Meet
Amy Schroeder
Principal Research Scientist
Amy Schroeder offers strategic guidance on issues related to clinical data, clinical practice guidelines, clinical decision support technologies (e.
g., clinical pathways), and drug and pharmacopeial compendia.
Amy leads the Clinical SME team of physicians, nurses, and pharmacists, and co-leads the technical science work track at Avalere Health. Amy leads primary research projects regarding the use of clinical decision support technologies that guide healthcare provider, payer, and patient care decisions, and provides real world expertise for inclusion/exclusion criteria and type of data to track in retrospective claims data analyses. Her perspective assists life science clients in understanding the landscape of different cancers, from screening, through diagnosis, treatment, and survivorship, and in interpreting the real-world experience of patients, barriers preventing access to critical treatments, and how to mitigate those barriers. Amy serves on the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) as a patient advocate for access to new technology and treatment advancements in oncology and endocrinology, and supports recognition of clinical drug compendia by CMS, for coverage determinations.
Amy began her clinical career in cancer research and subsequently held positions in retail, specialty, home infusion, and outpatient oncology pharmacies, as well as leadership roles developing clinical and pharmacopeial drug compendia. She helped to create the initial United States Pharmacopeia Medicare Model Guidelines to guide Part D plans in developing and maintaining their drug formularies, and drafted Level I clinical pathways content for US Oncology. She also provided consultation on the impacts of clinical drug data on payer coverage and reimbursement, subsequently becoming a senior consultant for Lash Group Healthcare Consultants and DK Pierce & Associates, Inc. At Resolution Health, Inc., an analytics subsidiary of Anthem, Inc., she served as the assistant director of clinical pharmacy research and development, assessing the alignment of claims data with evidence-based clinical guidelines, quality measures, and identifying cost-saving opportunities and safety concerns for members. Amy is the only pharmacist who has contributed to the content of three clinical drug compendia recognized by CMS and commercial payers, and helped draft the first iteration of the NCCN Drugs & Biologics Compenidum (NCCN Compendium®).
Amy holds a BS in science/microbiology from the Pennsylvania State University and a BS in pharmacy from the University of Maryland School of Pharmacy. She is a licensed pharmacist and has served as a preceptor to pharmacy students at several universities.